Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

NCT03844945 is registered in ClinicalTrials.gov with Aerie Pharmaceuticals as lead sponsor.

NCT NCT03844945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03844945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Lead sponsor
Aerie Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
March 19, 2019
Completion date
September 19, 2019
Enrollment
215 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open angle glaucoma